Aaron G Schmidt

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/8917475/publications.pdf

Version: 2024-02-01

61 papers	13,869 citations	61857 43 h-index	143772 57 g-index
77 all docs	77 docs citations	77 times ranked	24831 citing authors

#	Article	IF	Citations
1	Extracellular vimentin is an attachment factor that facilitates SARS-CoV-2 entry into human endothelial cells. Proceedings of the National Academy of Sciences of the United States of America, 2022, 119, .	3.3	75
2	An aluminum hydroxide:CpG adjuvant enhances protection elicited by a SARS-CoV-2 receptor binding domain vaccine in aged mice. Science Translational Medicine, 2022, 14, .	5.8	57
3	Rationally designed immunogens enable immune focusing following SARS-CoV-2 spike imprinting. Cell Reports, 2022, 38, 110561.	2.9	16
4	COVID-19-neutralizing antibodies predict disease severity and survival. Cell, 2021, 184, 476-488.e11.	13.5	586
5	Multiple SARS-CoV-2 variants escape neutralization by vaccine-induced humoral immunity. Cell, 2021, 184, 2372-2383.e9.	13.5	1,166
6	Coronavirus-Specific Antibody Cross Reactivity in Rhesus Macaques following SARS-CoV-2 Vaccination and Infection. Journal of Virology, 2021, 95, .	1.5	24
7	Rapid generation of potent antibodies by autonomous hypermutation in yeast. Nature Chemical Biology, 2021, 17, 1057-1064.	3.9	59
8	CD209L/L-SIGN and CD209/DC-SIGN Act as Receptors for SARS-CoV-2. ACS Central Science, 2021, 7, 1156-1165.	5.3	165
9	Immunogenicity of COVID-19 mRNA Vaccines in Pregnant and Lactating Women. JAMA - Journal of the American Medical Association, 2021, 325, 2370.	3.8	307
10	InÂvitro and inÂvivo functions of SARS-CoV-2 infection-enhancing and neutralizing antibodies. Cell, 2021, 184, 4203-4219.e32.	13.5	228
11	Early cross-coronavirus reactive signatures of humoral immunity against COVID-19. Science Immunology, 2021, 6, eabj2901.	5.6	67
12	Memory B cell repertoire for recognition of evolving SARS-CoV-2 spike. Cell, 2021, 184, 4969-4980.e15.	13.5	94
13	An AAV-based, room-temperature-stable, single-dose COVID-19 vaccine provides durable immunogenicity and protection in non-human primates. Cell Host and Microbe, 2021, 29, 1437-1453.e8.	5.1	53
14	Naive human B cells engage the receptor binding domain of SARS-CoV-2, variants of concern, and related sarbecoviruses. Science Immunology, 2021, 6, eabl5842.	5.6	33
15	Altering the Immunogenicity of Hemagglutinin Immunogens by Hyperglycosylation and Disulfide Stabilization. Frontiers in Immunology, 2021, 12, 737973.	2.2	11
16	Protein engineering strategies for rational immunogen design. Npj Vaccines, 2021, 6, 154.	2.9	26
17	An aluminum hydroxide:CpG adjuvant enhances protection elicited by a SARS-CoV-2 receptor-binding domain vaccine in aged mice. Science Translational Medicine, 2021, , eabj5305.	5.8	4
18	Persistence and decay of human antibody responses to the receptor binding domain of SARS-CoV-2 spike protein in COVID-19 patients. Science Immunology, 2020, 5, .	5.6	561

#	Article	IF	Citations
19	Single-shot Ad26 vaccine protects against SARS-CoV-2 in rhesus macaques. Nature, 2020, 586, 583-588.	13.7	765
20	Loss of Bcl-6-Expressing T Follicular Helper Cells and Germinal Centers in COVID-19. Cell, 2020, 183, 143-157.e13.	13.5	599
21	Distinct Early Serological Signatures Track with SARS-CoV-2 Survival. Immunity, 2020, 53, 524-532.e4.	6.6	334
22	Ad26 vaccine protects against SARS-CoV-2 severe clinical disease in hamsters. Nature Medicine, 2020, 26, 1694-1700.	15.2	275
23	SARS-CoV-2 Infection Depends on Cellular Heparan Sulfate and ACE2. Cell, 2020, 183, 1043-1057.e15.	13.5	860
24	Ultrasensitive high-resolution profiling of early seroconversion in patients with COVID-19. Nature Biomedical Engineering, 2020, 4, 1180-1187.	11.6	110
25	Clinical sensitivity and interpretation of PCR and serological COVIDâ€19 diagnostics for patients presenting to the hospital. FASEB Journal, 2020, 34, 13877-13884.	0.2	117
26	High Seroprevalence of Anti-SARS-CoV-2 Antibodies in Chelsea, Massachusetts. Journal of Infectious Diseases, 2020, 222, 1955-1959.	1.9	72
27	Quick COVID-19 Healers Sustain Anti-SARS-CoV-2 Antibody Production. Cell, 2020, 183, 1496-1507.e16.	13.5	182
28	Compromised Humoral Functional Evolution Tracks with SARS-CoV-2 Mortality. Cell, 2020, 183, 1508-1519.e12.	13.5	263
29	SARS-CoV-2 infection protects against rechallenge in rhesus macaques. Science, 2020, 369, 812-817.	6.0	789
30	DNA vaccine protection against SARS-CoV-2 in rhesus macaques. Science, 2020, 369, 806-811.	6.0	978
31	Gp41-targeted antibodies restore infectivity of a fusion-deficient HIV-1 envelope glycoprotein. PLoS Pathogens, 2020, 16, e1008577.	2.1	3
32	SARS-CoV-2 Receptor ACE2 Is an Interferon-Stimulated Gene in Human Airway Epithelial Cells and Is Detected in Specific Cell Subsets across Tissues. Cell, 2020, 181, 1016-1035.e19.	13.5	1,956
33	Structure-Guided Molecular Grafting of a Complex Broadly Neutralizing Viral Epitope. ACS Infectious Diseases, 2020, 6, 1182-1191.	1.8	18
34	Assessment of Maternal and Neonatal SARS-CoV-2 Viral Load, Transplacental Antibody Transfer, and Placental Pathology in Pregnancies During the COVID-19 Pandemic. JAMA Network Open, 2020, 3, e2030455.	2.8	315
35	Gp41-targeted antibodies restore infectivity of a fusion-deficient HIV-1 envelope glycoprotein. , 2020, 16, e1008577.		0
36	Gp41-targeted antibodies restore infectivity of a fusion-deficient HIV-1 envelope glycoprotein. , 2020, 16, e1008577.		0

#	Article	IF	Citations
37	Gp41-targeted antibodies restore infectivity of a fusion-deficient HIV-1 envelope glycoprotein. , 2020, 16, e1008577.		0
38	Gp41-targeted antibodies restore infectivity of a fusion-deficient HIV-1 envelope glycoprotein. , 2020, 16, e1008577.		0
39	Antibodies to a Conserved Influenza Head Interface Epitope Protect by an IgG Subtype-Dependent Mechanism. Cell, 2019, 177, 1124-1135.e16.	13.5	141
40	Influenza Antigen Engineering Focuses Immune Responses to a Subdominant but Broadly Protective Viral Epitope. Cell Host and Microbe, 2019, 25, 827-835.e6.	5.1	127
41	Autoreactivity profilesÂof influenza hemagglutinin broadly neutralizingÂantibodies. Scientific Reports, 2019, 9, 3492.	1.6	49
42	Self-tolerance curtails the B cell repertoire to microbial epitopes. JCI Insight, 2019, 4, .	2.3	32
43	Memory B Cells that Cross-React with Group 1 and Group 2 Influenza A Viruses Are Abundant in Adult Human Repertoires. Immunity, 2018, 48, 174-184.e9.	6.6	124
44	Conserved epitope on influenza-virus hemagglutinin head defined by a vaccine-induced antibody. Proceedings of the National Academy of Sciences of the United States of America, 2018, 115, 168-173.	3.3	113
45	Functional interrogation and mining of natively paired human VH:VL antibody repertoires. Nature Biotechnology, 2018, 36, 152-155.	9.4	109
46	CryoEM Structure of an Influenza Virus Receptor-Binding Site Antibodyâ€“Antigen Interface. Journal of Molecular Biology, 2017, 429, 1829-1839.	2.0	21
47	GNF-2 Inhibits Dengue Virus by Targeting Abl Kinases and the Viral E Protein. Cell Chemical Biology, 2016, 23, 443-452.	2.5	57
48	Complex Antigens Drive Permissive Clonal Selection in Germinal Centers. Immunity, 2016, 44, 542-552.	6.6	278
49	Influenza immunization elicits antibodies specific for an egg-adapted vaccine strain. Nature Medicine, 2016, 22, 1465-1469.	15.2	104
50	Immunogenic Stimulus for Germline Precursors of Antibodies that Engage the Influenza Hemagglutinin Receptor-Binding Site. Cell Reports, 2015, 13, 2842-2850.	2.9	67
51	Viral Receptor-Binding Site Antibodies with Diverse Germline Origins. Cell, 2015, 161, 1026-1034.	13.5	151
52	Key mutations stabilize antigenâ€bbinding conformation during affinity maturation of a broadly neutralizing influenza antibody lineage. Proteins: Structure, Function and Bioinformatics, 2015, 83, 771-780.	1.5	34
53	Sequential conformational rearrangements in flavivirus membrane fusion. ELife, 2014, 3, e04389.	2.8	72
54	Affinity maturation in an HIV broadly neutralizing B-cell lineage through reorientation of variable domains. Proceedings of the National Academy of Sciences of the United States of America, 2014, 111, 10275-10280.	3.3	73

#	Article	IF	Citations
55	Gain-of-Sensitivity Mutations in a Trim5-Resistant Primary Isolate of Pathogenic SIV Identify Two Independent Conserved Determinants of Trim5Î± Specificity. PLoS Pathogens, 2013, 9, e1003352.	2.1	26
56	Preconfiguration of the antigen-binding site during affinity maturation of a broadly neutralizing influenza virus antibody. Proceedings of the National Academy of Sciences of the United States of America, 2013, 110, 264-269.	3.3	227
57	Small-Molecule Inhibitors of Dengue-Virus Entry. PLoS Pathogens, 2012, 8, e1002627.	2.1	80
58	Peptide Inhibitors of Flavivirus Entry Derived from the E Protein Stem. Journal of Virology, 2010, 84, 12549-12554.	1.5	85
59	Peptide Inhibitors of Dengue-Virus Entry Target a Late-Stage Fusion Intermediate. PLoS Pathogens, 2010, 6, e1000851.	2.1	113
60	Escape and Compensation from Early HLA-B57-Mediated Cytotoxic T-Lymphocyte Pressure on Human Immunodeficiency Virus Type 1 Gag Alter Capsid Interactions with Cyclophilin A. Journal of Virology, 2007, 81, 12608-12618.	1.5	241
61	COVID-19 Neutralizing Antibodies Predict Disease Severity and Survival. SSRN Electronic Journal, 0, , .	0.4	9